Vascular endothelial growth factor (VEGF) is a key proangiogenic factor involved in the pathogenesis of ROP, promoting retinal neovascularization and prompting researchers to explore the effect of anti-VEGF agents in the management of ROP. Here, VEGFA is linked to retinopathy of prematurity.